Martin Gleave

Dr. Martin Gleave is a Canadian surgeon and cancer researcher who was appointed to the Order of Canada in 2018.[1]

Gleave is a co-founder and Executive Director of the Vancouver Prostate Centre as well as a head of a department at University of British Columbia.

Gleave's team was recognized in 2010 as the first in the world to develop an anti-clusterin agent.[2]

Awards

  • Richard D. Williams MD Prostate Cancer Research Excellence Award[3]
  • Eugene Fuller Triennial Prostate Award from the American Urological Association[3]
  • Barringer Medal from the American Association of Genitourinary Surgeons[3]
  • BC Biotech Innovation and Achievement Award[3]
  • BC Innovation Council Frontiers in Research Award[3]
  • 2013 Aubrey J. Tingle Prize from Michael Smith Foundation for Health Research[4]

References

  1. ↑ Li, Wanyee (January 4, 2018). "B.C. doctor inducted into Order of Canada for innovative cancer treatments". Metro News Vancouver. Retrieved January 10, 2018.
  2. ↑ Crawford, Tiffany (August 28, 2010). "New cancer drug will prolong lives, Vancouver scientists say". Vancouver Sun. Retrieved 9 January 2018.
  3. 1 2 3 4 5 "DR. MARTIN GLEAVE APPOINTED TO THE ORDER OF CANADA". Vancouver Coastal Health Research Institute. Retrieved January 9, 2018.
  4. ↑ "AJT Prize Recognizes Made-In-BC Advances In Prostate Cancer Treatment". msfhr.org. Retrieved January 9, 2018.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.